6-(2,6-dichlorophenyl)-8-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-5(8H)-one | 1431323-90-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 6-(2,6-dichlorophenyl)-8-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-5(8H)-one
• 英文别名: 6-(2,6-Dichlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-5-one；6-(2,6-dichlorophenyl)-8-methyl-2-methylsulfanylpyrido[2,3-d]pyrimidin-5-one
• CAS: 1431323-90-8
• 化学式: C₁₅H₁₁Cl₂N₃OS
• 分子量: 352.244
• InChiKey: YGVLTRWPWGSVDC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4
• 重原子数：
  22
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  71.4
• 氢给体数：
  0
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-(2,6-dichlorophenyl)-8-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-5(8H)-one 在 间氯过氧苯甲酸 、 三氟乙酸 作用下， 以 二氯甲烷 、 乙腈 为溶剂， 生成 6-(2,6-dichlorophenyl)-8-methyl-2-((2'-methyl-2',3'-dihydro-1'H-spiro[cyclopropane-1,4'-isoquinolin]-7'-yl)amino)pyrido[2,3-d]pyrimidin-5(8H)-one
  参考文献：
  名称：

  Investigation of biaryl heterocycles as inhibitors of Wee1 kinase

  摘要：

  In continuation of our previous research towards the discovery of potent, selective and drug-like Wee1 inhibitors, 2 novel series of biaryl heterocycles were designed, synthesized and evaluated. The new biaryl cores were designed to enable structure - activity exploration of substituents at C-8 or N-8 which were used for tuning compound properties and to improve compound profiles. The lead molecule 33 demonstrated a desirable pharmacokinetic profile and potentiated the anti-proliferative activity of irinotecan in vivo when dosed orally in the human breast MX-1 xenograft model.

  DOI：

  10.1016/j.bmcl.2019.04.017
• 作为产物：
  描述：

  1-(4-chloro-2-(methylthio)pyrimidin-5-yl)-2-(2,6-dichlorophenyl)ethanone 以 异丙醇 为溶剂， 反应 16.0h， 生成 6-(2,6-dichlorophenyl)-8-methyl-2-(methylthio)pyrido[2,3-d]pyrimidin-5(8H)-one
  参考文献：
  名称：

  Investigation of biaryl heterocycles as inhibitors of Wee1 kinase

  摘要：

  In continuation of our previous research towards the discovery of potent, selective and drug-like Wee1 inhibitors, 2 novel series of biaryl heterocycles were designed, synthesized and evaluated. The new biaryl cores were designed to enable structure - activity exploration of substituents at C-8 or N-8 which were used for tuning compound properties and to improve compound profiles. The lead molecule 33 demonstrated a desirable pharmacokinetic profile and potentiated the anti-proliferative activity of irinotecan in vivo when dosed orally in the human breast MX-1 xenograft model.

  DOI：

  10.1016/j.bmcl.2019.04.017

文献信息

• [EN] PHARMACEUTICAL COMPOUNDS<br/>[FR] COMPOSÉS PHARMACEUTIQUES
  申请人：ALMAC DISCOVERY LTD

  公开号：WO2015019037A1

  公开（公告）日：2015-02-12

  The present invention relates to compounds that are useful as inhibitors of the activity of Wee-1 kinase. The present invention also relates to pharmaceutical compositions comprising these compounds and to methods of using these compounds in the treatment of cancer and methods of treating cancer.

  本发明涉及一种作为Wee-1激酶活性抑制剂有用的化合物。本发明还涉及包含这些化合物的药物组合物，以及在癌症治疗中使用这些化合物的方法和治疗癌症的方法。
• PYRIDOPYRIMIDINONE INHIBITORS OF KINASES
  申请人：AbbVie Inc.

  公开号：US20130102590A1

  公开（公告）日：2013-04-25

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R 1 , R 2 , R 3 , R 4 , and B are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.

  本发明涉及式（I）的化合物或药用可接受的盐，其中R1、R2、R3、R4和B在描述中有定义。本发明还涉及含有上述化合物的组合物，用于抑制wee-1等激酶，并治疗癌症等疾病的方法。
• [EN] PYRIMIDINE DERIVATIVE AS WEE1 INHIBITOR<br/>[FR] DÉRIVÉ DE PYRIMIDINE UTILISÉ EN TANT QU'INHIBITEUR DE WEE1<br/>[ZH] 作为Wee1抑制剂的嘧啶衍生物
  申请人：WIGEN BIOMEDICINE TECH SHANGHAI CO LTD

  公开号：WO2021043152A1

  公开（公告）日：2021-03-11

  本发明涉及一种如式(1A)或式(1B)所示的新化合物和/或其药学上可接受的盐，以及含有如式(1A)或式(1B)所示化合物的组合物和/或其药学上可接受的盐，制备方法和其作为Wee1抑制剂在抗肿瘤药物制备中的用途。
• US9181239B2
  申请人：——

  公开号：US9181239B2

  公开（公告）日：2015-11-10
• [EN] PYRIDOPYRIMIDINONE INHIBITORS OF KINASES<br/>[FR] COMPOSÉS DE PYRIDOPYRIMIDINONE INHIBITEURS DE KINASES
  申请人：ABBVIE INC

  公开号：WO2013059485A1

  公开（公告）日：2013-04-25

  The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein R1, R2, R3, R4, and B are defined in the description. The present invention relates also to compositions containing said compounds which are useful for inhibiting kinases such as wee-1 and methods of treating diseases such as cancer.